ZA200203942B - Isoxazolecarboxamide derivatives. - Google Patents
Isoxazolecarboxamide derivatives. Download PDFInfo
- Publication number
- ZA200203942B ZA200203942B ZA200203942A ZA200203942A ZA200203942B ZA 200203942 B ZA200203942 B ZA 200203942B ZA 200203942 A ZA200203942 A ZA 200203942A ZA 200203942 A ZA200203942 A ZA 200203942A ZA 200203942 B ZA200203942 B ZA 200203942B
- Authority
- ZA
- South Africa
- Prior art keywords
- phenyl
- carboxamide
- piperazinyl
- propyl
- trifluoroethoxy
- Prior art date
Links
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical class NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 108
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 29
- -1 polyfluoroalkoxy Chemical group 0.000 claims description 29
- 239000002904 solvent Substances 0.000 claims description 29
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 21
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 12
- 238000009833 condensation Methods 0.000 claims description 11
- 230000005494 condensation Effects 0.000 claims description 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000001204 N-oxides Chemical class 0.000 claims description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 6
- 150000001408 amides Chemical class 0.000 claims description 6
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical class C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 claims description 6
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000004442 acylamino group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 4
- 125000005518 carboxamido group Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 150000008064 anhydrides Chemical class 0.000 claims description 3
- 239000000010 aprotic solvent Substances 0.000 claims description 3
- ZWWWLCMDTZFSOO-UHFFFAOYSA-N diethoxyphosphorylformonitrile Chemical compound CCOP(=O)(C#N)OCC ZWWWLCMDTZFSOO-UHFFFAOYSA-N 0.000 claims description 3
- 125000004193 piperazinyl group Chemical group 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- VBQXLSIMJIAZOB-UHFFFAOYSA-N n-[3-[4-(5-chloro-2-hydroxyphenyl)piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC(Cl)=CC=C1O VBQXLSIMJIAZOB-UHFFFAOYSA-N 0.000 claims description 2
- BXGFKBLMXSXOFE-UHFFFAOYSA-N n-[3-[4-[5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC(F)=CC=C1OCC(F)(F)F BXGFKBLMXSXOFE-UHFFFAOYSA-N 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- LYPXTDXYEQEIIN-UHFFFAOYSA-N 1,2-oxazole-4-carboxylic acid Chemical class OC(=O)C=1C=NOC=1 LYPXTDXYEQEIIN-UHFFFAOYSA-N 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- QYQWBSNRTSANPD-UHFFFAOYSA-N 3-(3-fluorophenyl)-5-methyl-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=C(F)C=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1OCC(F)(F)F QYQWBSNRTSANPD-UHFFFAOYSA-N 0.000 claims 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims 2
- 239000000460 chlorine Substances 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- LTMKIBSJYYJZHM-UHFFFAOYSA-N 3-(2,6-dichlorophenyl)-5-methyl-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1OCC(F)(F)F LTMKIBSJYYJZHM-UHFFFAOYSA-N 0.000 claims 1
- CVQNKARALCHNAS-UHFFFAOYSA-N 3-(2-chloro-6-fluorophenyl)-5-methyl-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2F)Cl)C=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1OCC(F)(F)F CVQNKARALCHNAS-UHFFFAOYSA-N 0.000 claims 1
- CIXALRUGDOXQKP-UHFFFAOYSA-N 3-(2-chloro-6-fluorophenyl)-n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2F)Cl)C=1C(=O)NCCCN(CC1)CCN1C1=CC=C(F)C=C1OCC(F)(F)F CIXALRUGDOXQKP-UHFFFAOYSA-N 0.000 claims 1
- BIBMRCVZOOVSSW-UHFFFAOYSA-N 3-(2-chlorophenyl)-5-methyl-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2)Cl)C=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1OCC(F)(F)F BIBMRCVZOOVSSW-UHFFFAOYSA-N 0.000 claims 1
- DOVMWSFHORVQLK-UHFFFAOYSA-N 3-(2-fluorophenyl)-n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C(=CC=CC=2)F)C=1C(=O)NCCCN(CC1)CCN1C1=CC=C(F)C=C1OCC(F)(F)F DOVMWSFHORVQLK-UHFFFAOYSA-N 0.000 claims 1
- MIBCESAHFHRICP-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1C1=NOC=C1C(=O)NCCCN1CCN(C=2C(=CC=CC=2)OCC(F)(F)F)CC1 MIBCESAHFHRICP-UHFFFAOYSA-N 0.000 claims 1
- DRZJSWSDRUEMMV-UHFFFAOYSA-N 3-phenyl-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound FC(F)(F)COC1=CC=CC=C1N1CCN(CCCNC(=O)C=2C(=NOC=2)C=2C=CC=CC=2)CC1 DRZJSWSDRUEMMV-UHFFFAOYSA-N 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- HIYCBQVPMIVUBY-UHFFFAOYSA-N 5-ethyl-n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CCC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC=C(F)C=C1OCC(F)(F)F HIYCBQVPMIVUBY-UHFFFAOYSA-N 0.000 claims 1
- XTOYTDCKZUBPSN-UHFFFAOYSA-N 5-methyl-3-phenyl-n-[3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC=CC=C1OCC(F)(F)F XTOYTDCKZUBPSN-UHFFFAOYSA-N 0.000 claims 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000011737 fluorine Substances 0.000 claims 1
- GTGAZWYJQUSCGR-UHFFFAOYSA-N n-[3-[4-(4-chloro-2-methylphenyl)piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC=C(Cl)C=C1C GTGAZWYJQUSCGR-UHFFFAOYSA-N 0.000 claims 1
- RJVCLYVOUSAALR-UHFFFAOYSA-N n-[3-[4-(4-fluoro-2-methylphenyl)piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC=C(F)C=C1C RJVCLYVOUSAALR-UHFFFAOYSA-N 0.000 claims 1
- WGZBIHYWWBZODW-UHFFFAOYSA-N n-[3-[4-(4-fluoro-2-propan-2-yloxyphenyl)piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CC(C)OC1=CC(F)=CC=C1N1CCN(CCCNC(=O)C=2C(=NOC=2C)C=2C=CC=CC=2)CC1 WGZBIHYWWBZODW-UHFFFAOYSA-N 0.000 claims 1
- VYMRMWQILRQHOS-UHFFFAOYSA-N n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound FC(F)(F)COC1=CC(F)=CC=C1N1CCN(CCCNC(=O)C=2C(=NOC=2)C=2C=CC=CC=2)CC1 VYMRMWQILRQHOS-UHFFFAOYSA-N 0.000 claims 1
- MVIKXLCFXZBTDQ-UHFFFAOYSA-N n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-3-phenyl-5-(2-phenylethyl)-1,2-oxazole-4-carboxamide Chemical compound FC(F)(F)COC1=CC(F)=CC=C1N1CCN(CCCNC(=O)C=2C(=NOC=2CCC=2C=CC=CC=2)C=2C=CC=CC=2)CC1 MVIKXLCFXZBTDQ-UHFFFAOYSA-N 0.000 claims 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 68
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 23
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 23
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- 239000000203 mixture Substances 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 108060003345 Adrenergic Receptor Proteins 0.000 description 18
- 102000017910 Adrenergic receptor Human genes 0.000 description 18
- 102000005962 receptors Human genes 0.000 description 18
- 108020003175 receptors Proteins 0.000 description 18
- 239000005557 antagonist Substances 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 206010071289 Lower urinary tract symptoms Diseases 0.000 description 13
- 229910052938 sodium sulfate Inorganic materials 0.000 description 13
- 235000011152 sodium sulphate Nutrition 0.000 description 13
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000003818 flash chromatography Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 9
- 239000012044 organic layer Substances 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 229960001289 prazosin Drugs 0.000 description 8
- 210000003708 urethra Anatomy 0.000 description 8
- 210000001635 urinary tract Anatomy 0.000 description 8
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 7
- 210000002307 prostate Anatomy 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229910021529 ammonia Inorganic materials 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 230000004064 dysfunction Effects 0.000 description 5
- 230000000414 obstructive effect Effects 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 4
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 4
- 229940126062 Compound A Drugs 0.000 description 4
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 125000001207 fluorophenyl group Chemical group 0.000 description 4
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 4
- 229960002748 norepinephrine Drugs 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000012258 stirred mixture Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- GDEFBLAPDVUMHR-UHFFFAOYSA-N tert-butyl 4-(5-hydroxy-2-methoxyphenyl)piperazine-1-carboxylate Chemical compound COC1=CC=C(O)C=C1N1CCN(C(=O)OC(C)(C)C)CC1 GDEFBLAPDVUMHR-UHFFFAOYSA-N 0.000 description 4
- DIOHEXPTUTVCNX-UHFFFAOYSA-N 1,1,1-trifluoro-n-phenyl-n-(trifluoromethylsulfonyl)methanesulfonamide Chemical compound FC(F)(F)S(=O)(=O)N(S(=O)(=O)C(F)(F)F)C1=CC=CC=C1 DIOHEXPTUTVCNX-UHFFFAOYSA-N 0.000 description 3
- FCZBQMUDGBEIHG-UHFFFAOYSA-N 1-(5-chloro-2-methoxyphenyl)piperazine Chemical compound COC1=CC=C(Cl)C=C1N1CCNCC1 FCZBQMUDGBEIHG-UHFFFAOYSA-N 0.000 description 3
- MWWCHMRATZTTMK-UHFFFAOYSA-N 1-[5-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazine Chemical compound FC1=CC=C(OCC(F)(F)F)C(N2CCNCC2)=C1 MWWCHMRATZTTMK-UHFFFAOYSA-N 0.000 description 3
- MCFBUIIRFZBRCU-UHFFFAOYSA-N 4-[1-[5-[6-(trifluoromethyl)-1h-benzimidazol-2-yl]pyridin-2-yl]piperidin-4-yl]oxycyclohexane-1-carboxylic acid Chemical compound C1CC(C(=O)O)CCC1OC1CCN(C=2N=CC(=CC=2)C=2NC3=CC(=CC=C3N=2)C(F)(F)F)CC1 MCFBUIIRFZBRCU-UHFFFAOYSA-N 0.000 description 3
- UWPYDJFNRSFERK-UHFFFAOYSA-N 4-chloro-2-piperazin-1-ylphenol;dihydrobromide Chemical compound Br.Br.OC1=CC=C(Cl)C=C1N1CCNCC1 UWPYDJFNRSFERK-UHFFFAOYSA-N 0.000 description 3
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229960002896 clonidine Drugs 0.000 description 3
- 230000009989 contractile response Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000001272 neurogenic effect Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 210000002460 smooth muscle Anatomy 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229960002613 tamsulosin Drugs 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZADZZEZAWMZYEC-UHFFFAOYSA-N 1-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazine Chemical group FC(F)(F)COC1=CC(F)=CC=C1N1CCNCC1 ZADZZEZAWMZYEC-UHFFFAOYSA-N 0.000 description 2
- RFJJHOFIPQGFDX-UHFFFAOYSA-N 3-(4-fluorophenyl)-n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-1,2-oxazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1C1=NOC=C1C(=O)NCCCN1CCN(C=2C(=CC(F)=CC=2)OCC(F)(F)F)CC1 RFJJHOFIPQGFDX-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010021639 Incontinence Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- QZVCTJOXCFMACW-UHFFFAOYSA-N Phenoxybenzamine Chemical compound C=1C=CC=CC=1CN(CCCl)C(C)COC1=CC=CC=C1 QZVCTJOXCFMACW-UHFFFAOYSA-N 0.000 description 2
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- OJFKUJDRGJSAQB-UHFFFAOYSA-N TAK-632 Chemical compound C1=C(NC(=O)CC=2C=C(C=CC=2)C(F)(F)F)C(F)=CC=C1OC(C(=C1S2)C#N)=CC=C1N=C2NC(=O)C1CC1 OJFKUJDRGJSAQB-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 206010046542 Urinary hesitation Diseases 0.000 description 2
- 230000001800 adrenalinergic effect Effects 0.000 description 2
- 239000000464 adrenergic agent Substances 0.000 description 2
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 description 2
- 229960004607 alfuzosin Drugs 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000001078 anti-cholinergic effect Effects 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011833 dog model Methods 0.000 description 2
- RUZYUOTYCVRMRZ-UHFFFAOYSA-N doxazosin Chemical compound C1OC2=CC=CC=C2OC1C(=O)N(CC1)CCN1C1=NC(N)=C(C=C(C(OC)=C2)OC)C2=N1 RUZYUOTYCVRMRZ-UHFFFAOYSA-N 0.000 description 2
- 229960001389 doxazosin Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 150000002545 isoxazoles Chemical class 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- HUGHPRZGNVXAJO-UHFFFAOYSA-N n-(3-chloropropyl)-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound ClCCCNC(=O)C1=C(C)ON=C1C1=CC=CC=C1 HUGHPRZGNVXAJO-UHFFFAOYSA-N 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 206010029446 nocturia Diseases 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229960003418 phenoxybenzamine Drugs 0.000 description 2
- 125000005544 phthalimido group Chemical group 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 2
- 229960001693 terazosin Drugs 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 230000003202 urodynamic effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FSKSLWXDUJVTHE-WEVVVXLNSA-N (ne)-n-[(4-fluorophenyl)methylidene]hydroxylamine Chemical compound O\N=C\C1=CC=C(F)C=C1 FSKSLWXDUJVTHE-WEVVVXLNSA-N 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- STALANBIHAODET-UHFFFAOYSA-N 1-[2-(2,2,2-trifluoroethoxy)phenyl]piperazine Chemical group FC(F)(F)COC1=CC=CC=C1N1CCNCC1 STALANBIHAODET-UHFFFAOYSA-N 0.000 description 1
- ZFZJUOFJMBDGRY-UHFFFAOYSA-N 1-[2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl]piperazine Chemical compound COC1=CC=C(OCC(F)(F)F)C=C1N1CCNCC1 ZFZJUOFJMBDGRY-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- IGKCQDUYZULGBM-UHFFFAOYSA-N 2,2,2-trifluoroethyl 4-methylbenzenesulfonate Chemical compound CC1=CC=C(S(=O)(=O)OCC(F)(F)F)C=C1 IGKCQDUYZULGBM-UHFFFAOYSA-N 0.000 description 1
- VKJCJJYNVIYVQR-UHFFFAOYSA-N 2-(3-bromopropyl)isoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(CCCBr)C(=O)C2=C1 VKJCJJYNVIYVQR-UHFFFAOYSA-N 0.000 description 1
- YMDZDFSUDFLGMX-UHFFFAOYSA-N 2-chloro-n-(2-chloroethyl)ethanamine;hydron;chloride Chemical compound [Cl-].ClCC[NH2+]CCCl YMDZDFSUDFLGMX-UHFFFAOYSA-N 0.000 description 1
- PRQWXHIYVWJSLK-UHFFFAOYSA-N 3-(4-fluorophenyl)-1,2-oxazole-4-carbonyl chloride Chemical compound C1=CC(F)=CC=C1C1=NOC=C1C(Cl)=O PRQWXHIYVWJSLK-UHFFFAOYSA-N 0.000 description 1
- XXDHPFKMYSLBDJ-UHFFFAOYSA-N 3-(4-fluorophenyl)-1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=CON=C1C1=CC=C(F)C=C1 XXDHPFKMYSLBDJ-UHFFFAOYSA-N 0.000 description 1
- NQTWNFUXHPFLLH-UHFFFAOYSA-N 3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propan-1-amine Chemical compound C1CN(CCCN)CCN1C1=CC=C(F)C=C1OCC(F)(F)F NQTWNFUXHPFLLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- IHPRVZKJZGXTBQ-UHFFFAOYSA-N 3-chloropropan-1-amine;hydron;chloride Chemical group Cl.NCCCCl IHPRVZKJZGXTBQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- ZHRLVDHMIJDWSS-UHFFFAOYSA-N 4-fluoro-2-nitrophenol Chemical compound OC1=CC=C(F)C=C1[N+]([O-])=O ZHRLVDHMIJDWSS-UHFFFAOYSA-N 0.000 description 1
- SJDUTHOKAJHJFQ-UHFFFAOYSA-N 4-methoxy-3-piperazin-1-ylphenol;dihydrobromide Chemical compound Br.Br.COC1=CC=C(O)C=C1N1CCNCC1 SJDUTHOKAJHJFQ-UHFFFAOYSA-N 0.000 description 1
- YEGURGWPKJYFKH-UHFFFAOYSA-N 5-fluoro-2-(2,2,2-trifluoroethoxy)aniline Chemical compound NC1=CC(F)=CC=C1OCC(F)(F)F YEGURGWPKJYFKH-UHFFFAOYSA-N 0.000 description 1
- PENHKTNQUJMHIR-UHFFFAOYSA-N 5-methyl-3-phenyl-1,2-oxazole-4-carboxylic acid Chemical compound OC(=O)C1=C(C)ON=C1C1=CC=CC=C1 PENHKTNQUJMHIR-UHFFFAOYSA-N 0.000 description 1
- RNMOMKCRCIRYCZ-UHFFFAOYSA-N Alvameline Chemical compound CCN1N=NC(C=2CN(C)CCC=2)=N1 RNMOMKCRCIRYCZ-UHFFFAOYSA-N 0.000 description 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020853 Hypertonic bladder Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 206010036940 Prostatic adenoma Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000906446 Theraps Species 0.000 description 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 description 1
- 206010046555 Urinary retention Diseases 0.000 description 1
- 206010046640 Urine flow decreased Diseases 0.000 description 1
- DMEPDNFRHUGNPT-UHFFFAOYSA-N [5-(diethylamino)-2-methylpent-3-yn-2-yl] 2-cyclohexyl-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC(C)(C)C#CCN(CC)CC)C1CCCCC1 DMEPDNFRHUGNPT-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000011861 acute hypotension Diseases 0.000 description 1
- 150000001266 acyl halides Chemical class 0.000 description 1
- 150000007929 acylimidazolides Chemical class 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 229950002988 alvameline Drugs 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000000538 analytical sample Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 125000000068 chlorophenyl group Chemical group 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002390 hyperplastic effect Effects 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000023127 incomplete bladder emptying Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 230000004410 intraocular pressure Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- DUCNHKDCVVSJLG-UHFFFAOYSA-N n-[3-[4-(2-methoxyphenyl)piperazin-1-yl]propyl]-3-methyl-4-oxo-2-phenylchromene-8-carboxamide Chemical compound COC1=CC=CC=C1N1CCN(CCCNC(=O)C=2C3=C(C(C(C)=C(O3)C=3C=CC=CC=3)=O)C=CC=2)CC1 DUCNHKDCVVSJLG-UHFFFAOYSA-N 0.000 description 1
- SQHTVRPURQIDEB-UHFFFAOYSA-N n-[3-[4-(5-chloro-2-methoxyphenyl)piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound COC1=CC=C(Cl)C=C1N1CCN(CCCNC(=O)C=2C(=NOC=2C)C=2C=CC=CC=2)CC1 SQHTVRPURQIDEB-UHFFFAOYSA-N 0.000 description 1
- COCBYEOMTHXEKA-UHFFFAOYSA-N n-[3-[4-[2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound COC1=CC=C(OCC(F)(F)F)C=C1N1CCN(CCCNC(=O)C=2C(=NOC=2C)C=2C=CC=CC=2)CC1 COCBYEOMTHXEKA-UHFFFAOYSA-N 0.000 description 1
- AYFKNTPIHXBIIL-UHFFFAOYSA-N n-[3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]piperazin-1-yl]propyl]-5-methyl-3-phenyl-1,2-oxazole-4-carboxamide Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C(=O)NCCCN(CC1)CCN1C1=CC=C(F)C=C1OCC(F)(F)F AYFKNTPIHXBIIL-UHFFFAOYSA-N 0.000 description 1
- LKPFBGKZCCBZDK-UHFFFAOYSA-N n-hydroxypiperidine Chemical compound ON1CCCCC1 LKPFBGKZCCBZDK-UHFFFAOYSA-N 0.000 description 1
- 239000000133 nasal decongestant Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 238000001525 receptor binding assay Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229950000334 temiverine Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- OOGJQPCLVADCPB-HXUWFJFHSA-N tolterodine Chemical compound C1([C@@H](CCN(C(C)C)C(C)C)C=2C(=CC=C(C)C=2)O)=CC=CC=C1 OOGJQPCLVADCPB-HXUWFJFHSA-N 0.000 description 1
- 229960004045 tolterodine Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- JLTRXTDYQLMHGR-UHFFFAOYSA-N trimethylaluminium Chemical compound C[Al](C)C JLTRXTDYQLMHGR-UHFFFAOYSA-N 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- BDIAUFOIMFAIPU-UHFFFAOYSA-N valepotriate Natural products CC(C)CC(=O)OC1C=C(C(=COC2OC(=O)CC(C)C)COC(C)=O)C2C11CO1 BDIAUFOIMFAIPU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI002173A IT1314191B1 (it) | 1999-10-18 | 1999-10-18 | Derivati isossazolcarbossamidici |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200203942B true ZA200203942B (en) | 2003-01-02 |
Family
ID=11383797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200203942A ZA200203942B (en) | 1999-10-18 | 2002-05-17 | Isoxazolecarboxamide derivatives. |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1226131B1 (es) |
JP (1) | JP2003512362A (es) |
KR (1) | KR20020038944A (es) |
CN (1) | CN1139579C (es) |
AR (1) | AR029400A1 (es) |
AT (1) | ATE256670T1 (es) |
AU (1) | AU757614B2 (es) |
BR (1) | BR0014851A (es) |
CA (1) | CA2385472A1 (es) |
DE (1) | DE60007347T2 (es) |
DK (1) | DK1226131T3 (es) |
ES (1) | ES2210033T3 (es) |
HK (1) | HK1044940A1 (es) |
HU (1) | HUP0203184A3 (es) |
IL (1) | IL148837A0 (es) |
IT (1) | IT1314191B1 (es) |
MX (1) | MXPA02003432A (es) |
MY (1) | MY120400A (es) |
NO (1) | NO20021803L (es) |
NZ (1) | NZ517884A (es) |
PL (1) | PL356990A1 (es) |
PT (1) | PT1226131E (es) |
RU (1) | RU2002113096A (es) |
WO (1) | WO2001029015A2 (es) |
ZA (1) | ZA200203942B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101022082B1 (ko) | 2005-10-11 | 2011-03-17 | 에프. 호프만-라 로슈 아게 | 아이소옥사졸 유도체 |
CA2628667A1 (en) | 2005-11-09 | 2007-05-18 | F. Hoffmann-La Roche Ag | 3-aryl-isoxazole-4-carbonyl-benzofuran derivatives |
JP5015172B2 (ja) | 2005-12-23 | 2012-08-29 | エフ.ホフマン−ラ ロシュ アーゲー | アリール−イソオキサゾロ−4−イル−オキサジアゾール誘導体 |
PL1968973T3 (pl) | 2005-12-27 | 2012-03-30 | Hoffmann La Roche | Pochodne aryloizoksazol-4-iloimidazolu |
RU2426732C2 (ru) | 2006-01-17 | 2011-08-20 | Ф. Хоффманн-Ля Рош Аг | АРИЛ-ИЗОКСАЗОЛ-4-ИЛ-ИМИДАЗО[1,2-a]ПИРИДИН, ПРИГОДНЫЙ ДЛЯ ЛЕЧЕНИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА ЧЕРЕЗ ПОСРЕДСТВО GABA-РЕЦЕПТОРОВ |
AU2007267183B2 (en) | 2006-05-31 | 2011-10-20 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
JP5416103B2 (ja) | 2007-06-22 | 2014-02-12 | エフ.ホフマン−ラ ロシュ アーゲー | イソオキサゾール−イミダゾール誘導体 |
US7943619B2 (en) | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
KR101175859B1 (ko) | 2007-12-04 | 2012-08-24 | 에프. 호프만-라 로슈 아게 | 이속사졸로-피라진 유도체 |
US7902201B2 (en) | 2007-12-04 | 2011-03-08 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
WO2010081851A1 (en) | 2009-01-14 | 2010-07-22 | Genoscience Pharma | Piperidin-4-ylpiperazine compounds for the treatment of hcv infection |
TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
MX2011011273A (es) | 2009-05-05 | 2011-11-04 | Hoffmann La Roche | Derivados de isoxazol-pirazol. |
US8410104B2 (en) | 2009-05-05 | 2013-04-02 | Hoffmann-La Roche Inc. | Pyridazines |
WO2010127976A1 (en) | 2009-05-05 | 2010-11-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyridine derivatives |
JP5478716B2 (ja) | 2009-05-05 | 2014-04-23 | エフ.ホフマン−ラ ロシュ アーゲー | 認識障害の処置において使用するためのgabaa受容体逆アゴニストとしてのイソオキサゾール−チアゾール誘導体 |
KR101354416B1 (ko) | 2009-05-07 | 2014-02-19 | 에프. 호프만-라 로슈 아게 | 감마-아미노부티르산 조절제로서 이속사졸-피리딘 유도체 |
US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
CN113121540B (zh) * | 2020-01-15 | 2024-01-26 | 鲁南制药集团股份有限公司 | 一种西格列汀游离碱的合成方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1254469B (it) * | 1992-02-25 | 1995-09-25 | Recordati Chem Pharm | Derivati benzopiranici e benzotiopiranici |
IT1266582B1 (it) * | 1993-07-30 | 1997-01-09 | Recordati Chem Pharm | Derivati (di)azacicloesanici e diazacicloeptanici |
DE4425146A1 (de) * | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
-
1999
- 1999-10-18 IT IT1999MI002173A patent/IT1314191B1/it active
-
2000
- 2000-10-10 MY MYPI20004718A patent/MY120400A/en unknown
- 2000-10-16 EP EP00992436A patent/EP1226131B1/en not_active Expired - Lifetime
- 2000-10-16 CN CNB008143226A patent/CN1139579C/zh not_active Expired - Fee Related
- 2000-10-16 PL PL00356990A patent/PL356990A1/xx not_active Application Discontinuation
- 2000-10-16 AT AT00992436T patent/ATE256670T1/de not_active IP Right Cessation
- 2000-10-16 CA CA002385472A patent/CA2385472A1/en not_active Abandoned
- 2000-10-16 BR BR0014851-2A patent/BR0014851A/pt not_active IP Right Cessation
- 2000-10-16 NZ NZ517884A patent/NZ517884A/en unknown
- 2000-10-16 KR KR1020027004663A patent/KR20020038944A/ko not_active Application Discontinuation
- 2000-10-16 DK DK00992436T patent/DK1226131T3/da active
- 2000-10-16 IL IL14883700A patent/IL148837A0/xx unknown
- 2000-10-16 RU RU2002113096/04A patent/RU2002113096A/ru not_active Application Discontinuation
- 2000-10-16 AU AU28347/01A patent/AU757614B2/en not_active Ceased
- 2000-10-16 DE DE60007347T patent/DE60007347T2/de not_active Expired - Fee Related
- 2000-10-16 PT PT00992436T patent/PT1226131E/pt unknown
- 2000-10-16 JP JP2001531815A patent/JP2003512362A/ja active Pending
- 2000-10-16 MX MXPA02003432A patent/MXPA02003432A/es not_active Application Discontinuation
- 2000-10-16 ES ES00992436T patent/ES2210033T3/es not_active Expired - Lifetime
- 2000-10-16 HU HU0203184A patent/HUP0203184A3/hu unknown
- 2000-10-16 WO PCT/EP2000/010144 patent/WO2001029015A2/en active IP Right Grant
- 2000-10-18 AR ARP000105475A patent/AR029400A1/es not_active Application Discontinuation
-
2002
- 2002-04-17 NO NO20021803A patent/NO20021803L/no not_active Application Discontinuation
- 2002-05-17 ZA ZA200203942A patent/ZA200203942B/en unknown
- 2002-08-13 HK HK02105918.6A patent/HK1044940A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
IT1314191B1 (it) | 2002-12-06 |
DK1226131T3 (da) | 2004-04-19 |
AU2834701A (en) | 2001-04-30 |
KR20020038944A (ko) | 2002-05-24 |
EP1226131A2 (en) | 2002-07-31 |
AU757614B2 (en) | 2003-02-27 |
NO20021803L (no) | 2002-06-17 |
IL148837A0 (en) | 2002-09-12 |
ES2210033T3 (es) | 2004-07-01 |
PT1226131E (pt) | 2004-05-31 |
HUP0203184A3 (en) | 2004-12-28 |
HUP0203184A2 (hu) | 2003-01-28 |
AR029400A1 (es) | 2003-06-25 |
RU2002113096A (ru) | 2003-11-10 |
CA2385472A1 (en) | 2001-04-26 |
DE60007347D1 (de) | 2004-01-29 |
CN1379767A (zh) | 2002-11-13 |
JP2003512362A (ja) | 2003-04-02 |
BR0014851A (pt) | 2002-06-11 |
EP1226131B1 (en) | 2003-12-17 |
HK1044940A1 (zh) | 2002-11-08 |
WO2001029015A2 (en) | 2001-04-26 |
NZ517884A (en) | 2003-08-29 |
WO2001029015A3 (en) | 2001-11-01 |
ATE256670T1 (de) | 2004-01-15 |
ITMI992173A0 (it) | 1999-10-18 |
MXPA02003432A (es) | 2002-08-20 |
CN1139579C (zh) | 2004-02-25 |
NO20021803D0 (no) | 2002-04-17 |
DE60007347T2 (de) | 2004-09-02 |
ITMI992173A1 (it) | 2001-04-18 |
PL356990A1 (en) | 2004-07-12 |
MY120400A (en) | 2005-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200203942B (en) | Isoxazolecarboxamide derivatives. | |
KR100787131B1 (ko) | Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 | |
EA008476B1 (ru) | Замещенные сульфонамиды, способ их получения и их применение в качестве лечебного средства для лечения расстройств цнс, ожирения и диабета типа ii | |
BRPI0619260A2 (pt) | derivados de oxadiazol com atividade de receptor ctrh2, composição farmacêutica que os compreende e uso dos referidos derivados | |
US6680319B2 (en) | Isoxazolecarboxamide derivatives | |
US6486163B1 (en) | Thienopyranecarboxamide derivatives | |
KR20010070997A (ko) | 비페닐 유도체 | |
MXPA04009142A (es) | Tiopirimidina e isotiazolpirimidina inhibidoras de quinasas. | |
US6403594B1 (en) | Benzopyran derivatives | |
EP1200445B1 (en) | Thienopyranecarboxamide derivatives | |
JPH0920755A (ja) | 両性型三環系化合物 | |
EP1222183B1 (en) | Benzopyran derivatives | |
KR100786336B1 (ko) | Hif―1 활성을 저해하는 화합물, 이의 제조방법 및이를 유효성분으로 함유하는 약학적 조성물 | |
WO2002060534A2 (en) | Selective alpha 1 antagonists a + d | |
US20020183290A1 (en) | Adrenergic receptor antagonists selective for both alpha1A-and alpha1D-subtypes and uses therefor | |
AU615621B2 (en) | Aminoketone derivatives and use thereof | |
JPH06287182A (ja) | アルキルグリシン誘導体 |